Stay updated on Ponatinib for Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Ponatinib for Medullary Thyroid Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added, and prior government-funding notices as well as Revision: v3.4.1 were removed. This change does not affect study content, eligibility criteria, or results.SummaryDifference0.5%

- Check21 days agoChange DetectedA site-wide funding notice was added and the page version updated from v3.4.0 to v3.4.1. No study details, inclusion criteria, or outcome measures were changed.SummaryDifference0.5%

- Check28 days agoChange DetectedAdds a glossary toggle and updates metadata labels (Last Update Submitted that Met QC Criteria; No FEAR Act Data) with the revision tag changed to v3.4.0 (from v3.3.4).SummaryDifference0.2%

- Check42 days agoChange DetectedRevision tag updated from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter updated to show Revision: v3.3.3 and remove references to HHS Vulnerability Disclosure and Revision: v3.3.2.SummaryDifference0.1%

- Check92 days agoChange DetectedRevision: v3.3.2 was added and revision v3.2.0 was removed.SummaryDifference0.1%

Stay in the know with updates to Ponatinib for Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ponatinib for Medullary Thyroid Cancer Clinical Trial page.